Seattle gene therapy biotech startup Immusoft raises $4.5M

Seattle-based biotech startup Immusoft raised one other $4.5 million and landed a $467,000 NIH grant to assist additional growth of its medicine that deal with genetic ailments.

Based in 2009, Immusoft develops immune cell know-how that makes use of blood cells from a affected person to create therapeutic proteins focused to deal with ailments. Its lead candidate, ISP-001, treats Mucopolysaccharidosis kind I, or MPS I, and has each orphan drug and uncommon pediatric illness designations from the FDA.

Traders within the new spherical embrace earlier backers Ikarian Capital, Mesa Verde Enterprise Companions, and Breakout Ventures.

The 12-person firm final 12 months raised a $20 million Sequence B spherical.

Sean Ainsworth, a veteran biotech government, leads the corporate as CEO. In 2018 he changed founder Matthew Scholz. Ainsworth beforehand based gene therapy firm RetroSense Therapeutics, which offered to Allergan in 2016 in a deal price as much as $555 million.

Back to top button

Adblock Detected

Please stop the adblocker for your browser to view this page.